Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

被引：44

作者：

van Weerden, W. M. ^{[1
]}

Bangma, C. ^{[1
]}

de Wit, R. ^{[2
]}

机构：

[1] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands

[2] Erasmus MC, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2009年 / 100卷 / 01期

关键词：

hormone refractory prostate cancer; xenografts; novel therapeutics; PSA biomarker; MITOXANTRONE PLUS PREDNISONE; ANDROGEN RECEPTOR; CELL-LINES; TUMOR-GROWTH; DOUBLE-BLIND; NUDE-MICE; DOCETAXEL; CHEMOTHERAPY; PROGRESSION; SURVIVAL;

D O I：

10.1038/sj.bjc.6604822

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.

引用

页码：13 / 18

页数：6

共 34 条

[11] Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice [J].

Kraaij, R ;

van Weerden, WM ;

de Ridder, CMA ;

Gussenhoven, EJ ;

Honkoop, J ;

Nasu, Y ;

Bangma, CH .

LABORATORY ANIMALS, 2002, 36 (02) :165-172

[12] Dietary intervention in prostate cancer patients:: PSA response in a randomized double-blind placebo-controlled study [J].

Kranse, R ;

Dagnelie, PC ;

van Kemenade, MC ;

de Jong, FH ;

Blom, JHM ;

Tijburg, LBM ;

Weststrate, JA ;

Schröder, FH .

INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (05) :835-840

[13] Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice [J].

Limpens, J ;

Schröder, FH ;

de Ridder, CMA ;

Bolder, CA ;

Wildhagen, MF ;

Obermüller-Jevic, UC ;

Krämer, K ;

van Weerden, WM .

JOURNAL OF NUTRITION, 2006, 136 (05) :1287-1293

[14]

Limpens J, 2005, ANN ONCOL, V16, P40

[15] Alterations of androgen receptor in prostate cancer [J].

Linja, MJ ;

Visakorpi, T .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 92 (04) :255-264

[16] Overexpression and gene amplification of BAG-IL in hormone-refractory prostate cancer [J].

Maki, H. E. ;

Saramaki, O. R. ;

Shatkina, L. ;

Martikainen, P. M. ;

Tammela, T. L. J. ;

van Weerden, W. M. ;

Vessella, R. L. ;

Cato, A. C. B. ;

Visakorpi, T. .

JOURNAL OF PATHOLOGY, 2007, 212 (04) :395-401

[17] The human PC346 xenograft and cell line panel: A model system for prostate cancer progression [J].

Marques, RB ;

van Weerden, WM ;

Erkens-Schulze, S ;

de Ridder, CM ;

Bangma, CH ;

Trapman, J ;

Jenster, G .

EUROPEAN UROLOGY, 2006, 49 (02) :245-257

[18] Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment [J].

Marques, RB ;

Erkens-Schulze, S ;

de Ridder, CM ;

Hermans, KG ;

Waltering, K ;

Visakorpi, T ;

Trapman, J ;

Romijn, JC ;

van Weerden, WM ;

Jenster, G .

INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) :221-229

[19] Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth [J].

Montgomery, R. Bruce ;

Mostaghel, Elahe A. ;

Vessella, Robert ;

Hess, David L. ;

Kalhorn, Thomas F. ;

Higano, Celestia S. ;

True, Lawrence D. ;

Nelson, Peter S. .

CANCER RESEARCH, 2008, 68 (11) :4447-4454

[20] Model systems of prostate cancer: Uses and limitations [J].

Navone, NM ;

Logothetis, CJ ;

von Eschenbach, AC ;

Troncoso, P .

CANCER AND METASTASIS REVIEWS, 1998, 17 (04) :361-371

← 1 2 3 4 →